Prof. Xianbo Zhou (周先波教授)

Team Member (Pharma, Bio-tech & Healthcare)

  • Professor Xianbo Zhou (MD, PhD) has over 27 years research experience (biochemistry, molecular and cellular biology) with 15+ years of industry managerial experience leading assay development, screening, in vitro/in vivo pharmacology, combined with vast drug discovery and development projects, managing large budgets.
  • Xianbo is currently Professor and Founding Director of the Center for Alzheimer’s Disease Research at Washington Institute of Clinical Research, Vienna, VA, USA.
  • He is also General Manager of SJN Biomed, Kunming, Yunnan, China, overseeing drug discovery and development efforts in the fields of anti-aging, CNS and oncology with initial focus on Alzheimer’s disease as well as oncology, and is managing collaboration with MemTrax LLC to bring MemTrax memory test product to the Chinese market place.
  • Xianbo is experienced in biotech start-up from the beginning: setting-up state-of-the-art molecular, cellular biology, high throughput screening and Drug Metabolism and Pharmacokinetics (DMPK) laboratories and establishing chemical hygiene and biosafety programs.
  • Established a wholly-foreign owned enterprise in Kunming, China from registration, facility renovation, hiring staff and having the company fully operational within 5 months from date of registration.

Education/Background:

  • Xianbo is experienced in identifying, selecting and dealing with contract research organizations (CROs) for both research and preclinical good laboratory practice (GLP) toxicity/safety studies for IND filing.
  • Participated in big pharmas’ due diligence of Aton Pharma as a part of Aton’s scientific team. Aton was acquired by Merck in 2004.
  • Participant on the team that developed the first-in-class histone deacetylase inhibitor Zolinza (vorinostat), which was approved in 2006.Board of Advisors, PEERChina (an NGO developing rural education projects in China).
  • 1997-2001, Postdoctoral training, Memorial Sloan-Kettering Cancer Center (MSKCC), New York.
  • 1991-1997, Ph.D., Biochemistry, State University of New York at Buffalo.
  • Thesis Title: Regulation of S-Adenosylhomocysteine Hydrolase Levels by Copper, Growth and During Development.
  • 1984-1990, Bachelor of Medicine (M.D. equivalent), Beijing Medical University (now Peking University Health Science Center), Beijing, China.
  • Chinese Associate of Medicine and Rehabilitation, Beijing, China.

  • 周先生（MD，PhD）拥有超过27年的研究经验（生物化学，分子和细胞生物学），拥有15年业界管理经验，领导了试剂开发，筛选，体外/体内药理学，广泛的药物发现和开发项目，和大型预算管理
  • 目前是美国弗吉尼亚州维华盛顿临床研究所阿尔茨海默病研究中心的教授和创始主任
  • 他还兼任云南昆明SJN Biomed公司总经理，负责在抗老化，中枢神经系统和肿瘤学等领域开展药物开发研究工作，初步研究阿尔茨海默病和肿瘤学，并与MemTrax LLC进行合作将MemTrax内存测试产品带到中国市场
  • 周博士很早就开始涉猎生物技术初创企业：建立了最先进的分子，细胞生物学，高通量筛选和药物代谢和药代动力学（DMPK）实验室，并建立化学卫生和生物安全计划
  • 从注册，设备翻新，招聘人员组建中国昆明的外商独资企业，并在注册日起5个月内全面运作
  • 经验丰富的鉴定，选择和处理合同研究机构（CRO），用于IND申报的研究和临床前良好实验室实践（GLP）毒性/安全性研究
  • 作为Aton科学团队的一部分参与了大型制药公司对Aton Pharma的尽职调查（Aton于2004年被Merck收购）
  • 参与开发了一流的组蛋白脱乙酰酶抑制剂Zolinza（vorinostat），于2006年获得批准
  • PEERChina（中国非政府组织在中国发展农村教育项目）的顾问
  • 1997-2001年，博士后培训，斯隆凯特林纪念癌症中心（MSKCC），纽约
  • 1991-1997年，纽约州立大学布法罗分校生物化学博士生（论文题目：铜，生长和发育过程中S-腺苷高半胱氨酸水解酶水平的调控）
  • 1984 – 1990年，北京医科大学（现北京大学健康科学中心）医学学士（美国医学博士同等学历）
  • 中国北京医学康复中心成员